Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Anti-CD70 is safe with hypomethylating agents in AML

Anti-CD70 is safe with hypomethylating agents in AML

Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland
ASH 2019

Prof. Adrian Ochsenbein (Bern University Hospital, Switzerland) presented the results of the open-label, non-randomised combined phase 1 and 2 study looking at newly diagnosed acute myeloid leukaemia (AML) treatment with hypomethylating agent azacitidine. These results showed that better clinical benefit could be achieved by the addition of the anti-CD70 monoclonal antibody cusatuzumab. Cusatuzumab in combination with azacitidine appeared safe and tolerable [1].

Leukaemia stem cells are known to express the surface markers CD70 and CD27, and there is substantial pre-clinical data to suggest that cusatuzumab blocks CD70–CD27 signalling. The authors hypothesised that combining cusatuzumab with azacitidine would eradicate leukaemia stem cells. This study provided the first-in-human data of this combination.

The study enrolled 12 patients with newly diagnosed AML, who received 1 infusion with cusatuzumab, ranging from 1-20 mg/kg, followed after 14 days ...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on